Long-term outcomes with pimavanserin for psychosis in clinical practice

@article{Akbar2022LongtermOW,
  title={Long-term outcomes with pimavanserin for psychosis in clinical practice},
  author={Umer Akbar and Joseph H. Friedman},
  journal={Clinical Parkinsonism \& Related Disorders},
  year={2022},
  volume={6}
}
  • U. Akbar, J. Friedman
  • Published 1 April 2022
  • Medicine, Psychology
  • Clinical Parkinsonism & Related Disorders
1 Citations
Clozapine
  • Reactions Weekly
  • 2022

References

SHOWING 1-10 OF 16 REFERENCES
A Retrospective Study of Pimavanserin Use in a Movement Disorders Clinic
  • J. Friedman
  • Medicine, Psychology
    Clinical neuropharmacology
  • 2017
TLDR
Pimavanserin, a 5-HT2A inverse agonist, was commercially released in the United States in April 2016 for the treatment of Parkinson disease psychosis and charts from the movement disorders clinic were reviewed for all patients who received this drug.
Pimavanserin for Psychosis in Parkinson’s Disease-Related Disorders: A Retrospective Chart Review
TLDR
Clinical improvement in psychosis was documented in 76% of patients and did not differ based on diagnosis, presence of dementia, delusions, use of deep brain stimulation, or prior antipsychotic failure, and long-term efficacy and tolerability of pimavanserin was emphasized.
Pimavanserin for Psychotic Symptoms in People With Parkinsonism: A Second Chart Review
  • J. Friedman
  • Medicine, Psychology
    Clinical neuropharmacology
  • 2018
TLDR
Almost 50% of parkinsonian patients with psychotic symptoms found Pim to be a useful medication, which they continue to take, according to a chart review of all patients started on the drugs since the one earlier report.
Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis.
Pimavanserin: A Novel Drug Approved to Treat Parkinson's Disease Psychosis.
TLDR
Evidence suggests pimavanserin attenuates PDP symptoms with few adverse effects and little risk of worsening motor function, and represents an important therapeutic innovation with limited treatment options for PDP.
Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review
TLDR
To update evidence‐based medicine recommendations for treating nonmotor symptoms in Parkinson's disease, the World Health Organization (WHO) selected Austria as a preferred destination for research and clinical trials.
Pimavanserin evaluated by the FDA
Double‐blind, placebo‐controlled, unforced titration parallel trial of quetiapine for dopaminergic‐induced hallucinations in Parkinson's disease
TLDR
Quetiapine, up to 200 mg daily, was well tolerated and did not worsen UPDRS scores; however, there was no significant improvement in psychosis rating scales compared to placebo.
...
...